---
title: "Structure Therapeutics appoints Matthew Lang as COO and General Counsel"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/282823641.md"
description: "Structure Therapeutics has appointed Matthew Lang as Chief Operating Officer and General Counsel, effective April 15, 2026. Lang previously held roles such as Chief Legal Officer at Metsera and CBO at Lyell, among others. The reason for his appointment and replacement information have not been disclosed. This announcement is documented in an SEC filing."
datetime: "2026-04-15T10:13:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/282823641.md)
  - [en](https://longbridge.com/en/news/282823641.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/282823641.md)
---

# Structure Therapeutics appoints Matthew Lang as COO and General Counsel

**Structure Therapeutics appointed Matthew Lang as Chief Operating Officer and General Counsel, effective April 15, 2026.**

Individual

Matthew Lang

Role

Chief Operating Officer and General Counsel

Type of Change

Appointed

Effective Date

April 15, 2026

Reason

Not disclosed

Replacement Info

Not disclosed

Background Details

Previously Chief Legal Officer & Corporate Secretary at Metsera (Apr 2025–Feb 2026); CBO & Chief Legal Officer at Lyell (Jul 2023–Apr 2025); various executive legal roles at Myovant (2017–2023); VP at Gilead (2009–2017); attorney at Dechert (2003–2009). JD, Univ. of Pennsylvania Law School.

Board/Committee Role Changes

Not disclosed

Original SEC Filing: Structure Therapeutics Inc. \[ GPCR \] - 8-K - Apr. 15, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [GPCR.US](https://longbridge.com/en/quote/GPCR.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [MTSR.US](https://longbridge.com/en/quote/MTSR.US.md)
- [LYEL.US](https://longbridge.com/en/quote/LYEL.US.md)
- [GILD.US](https://longbridge.com/en/quote/GILD.US.md)

## Related News & Research

- [Eton Secures U.S. IMPAVIDO Rights; $4.25M Fees, Up To $4M Milestones And 50-55% Revenue Share](https://longbridge.com/en/news/286966420.md)
- [Shah Capital Management Will Vote ‘No' Across Five Proposals On Novavax's June 18 Ballot - SEC Filing](https://longbridge.com/en/news/286565204.md)
- [Capricor publishes investor presentation on deramiocel Duchenne muscular dystrophy program](https://longbridge.com/en/news/287222906.md)
- [Wave Life Sciences posts positive RestorAATion-2 data; WVE-006 restores M-AAT, cuts Z-AAT, supports monthly dosing](https://longbridge.com/en/news/286818220.md)
- [Eton Pharmaceuticals Adds Another 2026 Launch As It Secures U.S. Rights To IMPAVIDO](https://longbridge.com/en/news/287025596.md)